Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m |
|||
Line 12: | Line 12: | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
+ | [[Category:Anti-CD22 antibodies]] | ||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 17:55, 26 November 2014
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article